Axxess Pharma, Inc. Enters $35 Billion Arthritis Market Acquiring Canadian Distribution Rights of Unique Pain Relief Medication
December 15 2010 - 3:01PM
Marketwired
Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to announce the
acquisition of FORTEX Rubbing Oil® from Actium Pharmaceuticals,
Inc. The acquisition now provides Axxess Pharma quick entry into
the $35 billion arthritis market. FORTEX is currently sold in 20
countries worldwide. Under the terms of the acquisition, Axxess
Pharma now has exclusive distribution rights throughout Canada.
FORTEX is a topical medication requested by physicians on a
daily basis. The medication provides rapid and lasting relief of
pain associated with musculoskeletal conditions, such as arthritis
and soft tissue injuries. Once applied to the skin, FORTEX is
readily absorbed directly down to the site of pain. Topical
medications such as FORTEX are rapidly expanding due to patients no
longer choosing to experience painful side effects caused by their
oral pain medication. These side effects are well documented by
medical professionals and patients and range from mild, severe and
sometimes fatal reactions.
Locally acting topical medications such as FORTEX have the
potential to exhibit a safer side effect profile as they deliver
the drug directly to the pain site through the skin, resulting in
lower levels of the active ingredient entering the blood stream
compared to oral medications. Axxess Pharma anticipates strong
sales due to demand in the Canadian market.
According to the Arthritis Society of Canada, over 4 million
Canadians are diagnosed with arthritis resulting in over 8.8
million physician visits per year for arthritis and related
conditions. These numbers are anticipated to continue to increase
due to the aging population and obesity.
"I am pleased with Axxess Pharma's business relationship, and
the prospects it brings for FORTEX in the Canadian market. FORTEX
possesses a unique position for this market. The product works and
allows clinicians and patients a cost-effective way to manage
musculoskeletal pain and discomfort. This is accomplished by
enabling the replacing, decreasing, or adding to, oral-NSAID
therapy, which is costly and comes with risks," said Michel
Lockhart, representative for Actium Pharmaceuticals.
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that
focuses on the marketing of dermatological, therapeutic
nutritionals, pain management and diagnostic products in Canada and
abroad since 1997. Axxess owns 22 established pharmaceutical
prescription products that have proven sales in Canada and
internationally. The company has an experienced management team and
field sales force to market products nationally to hospitals and
retail pharmacies as well as specialized practice areas including
Dermatology and Nephrology, Neurology and Urology.
Safe Harbor
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 info@theStockAlerts.com www.thestockalerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024